Keros Therapeutics (KROS) Receivables (2021 - 2025)

Keros Therapeutics (KROS) has reported Receivables for 4 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Receivables rose 30.09% year-over-year to $3.6 million; the trailing twelve-month figure through Dec 2025 stood at $3.6 million (up 30.09% YoY), and the FY2025 full-year result was $3.6 million, up 30.09% from the prior year.
• Receivables improved to $3.6 million in Q4 2025 per KROS's latest filing, from $3.5 million in the prior quarter.
• Across five years, Receivables topped out at $18.0 million in Q4 2021 and bottomed at $4000.0 in Q2 2024.
• Historically, Receivables has averaged $5.6 million across 4 years, with a median of $2.7 million in 2024.
• The widest YoY moves for Receivables: up 395300.0% in 2025, down 30.09% in 2025.
• Over 4 years, Receivables stood at $18.0 million in 2021, then plunged by 99.21% to $143000.0 in 2023, then soared by 1817.48% to $2.7 million in 2024, then surged by 30.09% to $3.6 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $3.6 million, $3.5 million, and $15.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.